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Abstract
High tumor kallikrein-related-peptidase 4 (KLK4) levels are associated with a poor outcome for women with serous epithelial
ovarian cancer (EOC), for which peritoneal dissemination and chemoresistance are key events. To determine the role of KLK4
in these events, we examined KLK4-transfected SKOV-3 and endogenous KLK4 expressing OVCA432 cells in 3-dimensional
(3D) suspension culture to mimic the ascites microenvironment. KLK4-SKOV-3 cells formed multicellular aggregates (MCAs)
as seen in ascites, as did SKOV-3 cells treated with active KLK4. MCA formation was reduced by treatment with a KLK4
blocking antibody or the selective active site KLK4 sunflower trypsin inhibitor (SFTI-FCQR). KLK4-MCAs formed larger cancer
cell foci in mesothelial cell monolayers than those formed by vector and native SKOV-3 cells, suggesting KLK4-MCAs are
highly invasive in the peritoneal microenvironment. A high level of KLK4 is expressed by ascitic EOC cells compared to
matched primary tumor cells, further supporting its role in the ascitic microenvironment. Interestingly, KLK4 transfected
SKOV-3 cells expressed high levels of the KLK4 substrate, urokinase plasminogen activator (uPA), particularly in 3D-
suspension, and high levels of both KLK4 and uPA were observed in patient cells taken from ascites. Importantly, the KLK4-
MCAs were paclitaxel resistant which was reversed by SFTI-FCQR and to a lesser degree by the general serine protease
inhibitor, Aprotinin, suggesting that in addition to uPA, other as yet unidentified substrates of KLK4 must be involved.
Nonetheless, these data suggest that KLK4 inhibition, in conjunction with paclitaxel, may improve the outcome for women
with serous epithelial ovarian cancer and high KLK4 levels in their tumors.
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Introduction
Serous epithelial ovarian carcinoma (EOC) accounts for .50%
of ovarian cancer [1] which is the leading cause of death from
gynecological malignancies [2]. Approximately 75% of women
with EOC are diagnosed when tumors have spread into the
peritoneal cavity [3] and ,70% of these patients accumulate
ascites [4]. Distinct from other solid tumors, EOC metastasis
occurs as the tumor cells are shed from the primary site and form
multicellular aggregates (MCAs) in the 3-dimensional (3D)-
suspension ascites microenvironment, before adhering to the
peritoneal surface and establishing secondary tumors in the
underlying extracellular matrix (ECM) [5].
Survival in the ascites microenvironment is crucial for EOC
cells to succeed in peritoneal dissemination. Although the
underlying mechanism is not clear, it is known that the ascitic
EOC cells are biologically different from their counterparts in the
solid matrices of primary and metastatic sites [6]. For example, cell
adhesion proteins E-cadherin [7] and a5/av/b1 integrins [8] are
highly expressed in ascites-derived ovarian cancer cells compared
to those from primary or metastatic tumor sites. Of note, the serine
protease, urokinase plasminogen activator (uPA) and its receptor
uPAR in EOC cells are induced by ascites [9] and the expression
of uPA is associated with chemoresistance, progression and poor
prognosis in women with this cancer [10,11]. These studies
indicated that the tumor microenvironment clearly influences
EOC progression [12,13], but the effect of suspension per se, thus
mimicking the ascites microenvironment, on survival of EOC cells
and chemosensitivity is not clear. In particular, the involvement of
other serine proteases remains largely unknown.
The kallikrein-related-peptidase (KLK) family comprises 15
serine peptidases that have shown their potential as biomarkers in
human cancers [14,15,16]. These peptidases degrade ECM
proteins and activate growth factors and other proteases, such as
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the uPA/uPAR axis [17,18], that play a role in human cancer
progression [14,15,16]. In ovarian cancer, KLK4-KLK8, KLK10
and KLK14 are upregulated [14,15,19,20] and we previously
reported that KLK4 and KLK7 were highly expressed in the most
lethal histotype, serous EOCs [21,22]. Recently, we showed that
high KLK7 levels are associated with poor prognosis and
chemoresistance in women with serous EOC and that KLK7
induces MCA of SKOV-3 cells, most likely through an integrin
related mechanism [23]. Given that high KLK4 levels are also
reported to be associated with poor prognosis [24] and chemo-
resistance [25], in this study, we aimed to determine whether a
similar, perhaps KLK-specific, functional mechanism was occur-
ring. We show here that, like for KLK7, KLK4-over-expression in
SKOV-3 cells promotes MCA formation and paclitaxel resistance
in 3D-suspension cultures that mimic the ascites microenviron-
ment, but unlike that seen in KLK7-SKOV-3 cells we found no
association with integrin expression. However, KLK4 overex-
pressing SKOV-3 cells displayed upregulated levels of uPA,
particularly in 3D-suspension MCAs. Importantly, KLK4 inhibi-
tion reduced MCA compaction and increased paclitaxel sensitivity
in KLK4-MCAs. This data suggests that although several KLKs
are over-expressed in EOC and may be similarly associated with
EOC progression, the underlying mechanism of action will be
related to the specific selective enzyme specificity of each KLK
peptidase.
Materials and Methods
Materials
Antibodies used include those against V5 epitope tagged at the
C-terminal of KLK4 (Invitrogen, Mount Waverley, VIC,
Australia); a KLK4 catalytic-domain antibody, KLK4 functional
blocking antibody (R&D Systems, Bio-Scientific Pty. Ltd, Gymea,
NSW, Australia); monoclonal anti-uPA B-chain (American Diag-
nostica, Stamford, CT, USA); GAPDH and an anti-mouse IgG
(Sigma Aldrich Pty Ltd, Castle Hill, NSW, Australia). Mouse and
rabbit Alexa Fluor 488 secondary antibodies, Alexa Fluor 568
phalloidin and CellTracker492 were from Invitrogen. The gener-
ation of active recombinant KLK4 [26] and the selective active
site KLK4 sunflower trypsin inhibitor (SFTI-FCQR) [27] are as
published. Site-directed mutagenesis was used to generate the
catalytic triad serine to alanine mutant-KLK4S207A (KLK4S/A)
plasmid. All other chemicals were from Sigma except where noted.
Human Cell Lines, and Patient Serous EOC Biopsies and
Ovarian Tissue RNA
The SKOV-3 serous EOC and LP9 peritoneal mesothelial cell
lines were from American Type Culture Collection and Coriell
Cell Repositories respectively. The OVCA432 cell line was
established from ascites obtained from an EOC patient [28] and
is a generous gift from Dr. Samuel Mok (MD Anderson Cancer
Center, Houston, TX, USA). The origin of patient EOC cells is
described previously [21,22]. The serous EOC tissue RNA
samples were described previously [23]. Patient clinical informa-
tion was obtained from Royal Brisbane and Women’s Hospital
(Supplementary Table S1). Ethical approval was obtained from
institutional ethics committees (Human Research Ethic Commit-
tee of Queensland University of Technology (#0800000213) and
The Clinical and Statewide Services Research Committee (#229));
written consent was obtained from all patients.
RNA Extraction, Reverse Transcription-PCR (RT-PCR)
Total RNA extraction and synthesis of cDNA are described
previously [23]. Quantitative-RT-PCR was performed for 40
cycles on an ABI7300 thermal cycler (Applied Biosystems,
Mulgrave, VIC, Australia) using KLK4 specific primers (K4Ex2qS,
59-GGCACTGGTCATGGAAAACGA-39 and K4Ex3qAS, 59-
TCAAGACTGTGCAGGCCCAGCC-39) and SYBR green as
per manufacturer’s instructions. KLK4 expression was normalized
to 18S (18SFor, 59- GATCCATTGGAGGGCAAGTCT-39 and
18SRev, 59-CCAAGATCCAACTACGAGCTTTTT-39) using
the standard curve method and RT-PCR was performed as
previously described [23].
Generation of Stable Cell Lines
Generation and transfection of the plasmid (pcDNA3.1/V5-
His, C-terminal V5 tag, Invitrogen) expressing the wild-type pre-
pro-KLK4 was described previously [29]. The catalytic triad
serine to alanine mutant-KLK4S207A (KLK4S/A) plasmid was
generated by site-directed mutagenesis. Stable monoclonal KLK4-
expressing or vector control cells were selected using G418
(Invitrogen), and 3 over-expressing clones, KLK4-1, KLK4-2 and
KLK4-3, were randomly selected for the following in vitro
functional assays.
In vitro Functional Assays
In vitro migration assays. 26105 cells in RPMI-1640
containing 0.1% BSA were seeded in tissue culture inserts with
8 mm pores (BD Biosciences, Eight Mile Plains, QLD, Australia),
and allowed to migrate towards 10% FCS as the chemoattractant
in the lower chamber for 24 hours (h). The number of migrated
cells was quantified using crystal violet staining read at 595 nm.
Multicellular aggregate (MCA)/spheroid formation and
inhibition. The hanging-drop method [30] was used for MCA
formation of all transfected and native cells with 56103 cells/well
in the presence of 10% FCS RPMI-1640 (100 ml) on top of
agarose-coated plates (60 ml of 0.5% agarose/serum-free media,
w/v) and incubated at 37uC. When recombinant active KLK4
(rKLK4) enzyme and catalytic inactive mutant KLK4S/A (50 ng/
ml) were used to induce MCA formation of SKOV-3 cells, this was
performed under serum free conditions. Serum free RPMI-1640
was used for MCA inhibition with the KLK4 blocking antibody at
a concentration (10 mg/ml) to capture all active enzyme with a
mouse IgG (10 mg/ml) control. KLK4 active site sunflower trypsin
inhibitor (SFTI-FCQR, 1 mM) [27] or PBS controls were added
into 10% FCS RPMI-1640. Images were taken using a Nikon-
Eclipse TE2000-U digital camera (46objectives) and V++
software. Compact MCAs were defined as those with $30 mm
diameter. To quantify the percentage of cells that formed compact
MCAs ($30 mm), all visible spheroids (,30 mm, $30 mm) were
counted at all time points and were divided by the number at 4 h,
the time point chosen to allow the cells to settle in the well. The
difference of overall spheroid numbers and those with ,30 mm
diameters on day 1, 4 and 7 from 4 h was calculated and was
considered the percentage of compact MCAs formed. This
approach was based on a previous report by Iwanicki et al [31].
In vitro mesothelial clearance assay. LP9 mesothelial cells
(5,000) were seeded in 96-well plates and grown to ,80%
confluence. MCAs were washed in PBS, incubated in Cell-
Tracker492 (4 mM), added on top of mesothelial monolayers (,4–6
spheroids/well/200 ml) and cultured at 37uC. At 4 h, 1, 2, 3 and 7
days from the initial spheroid plating, images were taken with a
106objective. To quantify MCA clearance, the diameter of the
fluorescent areas of MCAs labeled with CellTracker492 was
measured using InDesign software (Adobe, Adobe Systems Pty
Ltd, Chatswood, NSW, Australia). Measurements were performed
on 10 randomly selected MCAs from 3 separate experiments for
KLK4 and Chemoresistance in Ovarian Cancer
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e57056
the average diameter on day 3 in comparison to that of the initial
area of the spheroid (4 h).
Cell survival post cisplatin/paclitaxel treatment. 24 h
after seeding in uncoated 96-well plates (Nunc) as 2D-monolayers,
cells were treated with cisplatin (0, 1, 5, 10, 50 mM) or paclitaxel
(0, 0.01, 0.1, 1, 10 nM). In 3D-suspension cultures, spheroids were
formed as above for 4 days and then cisplatin or paclitaxel was
added. For KLK4 inhibition in 3D-suspension, the KLK4-1 or
OVCA432 cells were resuspended in SFTI-FCQR (1 mM)
containing media and seeded, and on day 4 paclitaxel (0, 0.1, 1,
10, 50, 100 nM) was added. WST-1 assays were performed 96 h
after treatment. Cell survival was calculated as the percentage of
absorbance of non-treated cells.
Knockdown of KLK4 Expression
Knockdown of KLK4 expression was performed as described
previously [26]. Briefly, the mammalian siRNA expression vector
pSilencer 3.1-H1 puro (Ambion, Austin, TX, USA) was used to
reduce expression of KLK4. Candidate KLK4 siRNA target
sequences were designed with the Ambion siRNA program and
then aligned against the human genome data base using the
BLAST algorithm to eliminate those with significant homology to
other genes. Two sequences selected were 59-GATC-
CATCCCTGGGGCTGGTTCCTTTCAAGAGAAGGAAC-
CAGCCCCAGGGATTTTTTTGGAAA-39 (psilK4Ex1) and 59-
GATCCAACGAATTGTTCTGCTCGGTTCAAGAGACC-
GAGC- AGAACAATTCGTTTTTTTTGGAAA-39
(psilK4Ex2). The oligos were synthesized (Sigma) and inserted
into the pSilencer 3.1-H1 puro vector (Ambion) according to the
manufacturer’s instructions. SKOV-3 stably expressing KLK4
(KLK4-1 clone) cells were transfected with the KLK4 pSilencer
3.1-H1 constructs or the supplied pSilencer 3.1-H1 negative
control using Lipofectamine (Invitrogen). After 48 h, whole cell
lysate was collected from transfected cells and expression of KLK4
and uPA was examined by Western blot analysis.
Western Blotting
Whole cell lysates from cells cultured as monolayer for 3 days
were collected in a buffer containing Complete protease inhibitor
cocktail (16, Roche Applied Sciences, Castle Hill, NSW,
Australia), 50 mM Tris-HCl (pH 7.4), NaCl (150 mM) and
CHAPS (1%). Cells cultured in 3D-collagen I, 3D-MatrigelTM
(BD Biosciences) and 3D-suspension for 7 days were collected into
ice-cold PBS followed by the procedure above. Protein concen-
tration was determined by the microbicinchoninic acid assay
(Thermo Fisher Scientific, Scoresby, VIC, Australia). Cell lysates
(20 mg) or conditioned media (CM, 4 mg protein) were separated
by SDS-PAGE under reducing conditions, transferred to nitro-
cellulose membranes, and blocked in Odyssey blocking buffer (LI-
CORH Biosciences, Lincoln, NE, USA). Membranes were
incubated with primary antibodies diluted in blocking buffer
overnight at 4uC, washed with tris-buffered saline containing
0.05% Tween-20, and then incubated with secondary IRDye 680
or 800 conjugated mouse or rabbit IgG (LI-CORH Biosciences) as
appropriate. Images were generated and densitometry analysis was
performed using the Odyssey system and software (LI-CORH
Biosciences).
Confocal Microscopy
Cells grown on sterile cover-slips until 80% confluent or MCAs
collected in eppendorf tubes after 7 days culture were fixed (4%
w/v paraformaldehyde/PFA in PBS), permeabilized (0.5% v/v
triton X-100 in PBS) and blocked (5% w/v bovine serum
albumin/BSA in PBS). Incubation with primary antibodies against
KLK4 and E-Cadherin (1/200 v/v in 1% BSA in PBS) was at 4uC
overnight. Alexa Fluor 568 phalloidin and 49-6-diamidino-2-
phenylindole (DAPI, Sigma) were applied with secondary Alexa
Fluor 488 IgG as appropriate. To obtain the images of MCA
clearance, monolayer mesothelial LP9 cells were seeded in an 8-
chamber slide (In vitro Technologies, Noble Park North, VIC,
Australia), CellTracker492 was applied for KLK4-1 spheroids prior
to seeding and 24 h later, cells were fixed as above followed by
staining of Alexa Fluor 568 phalloidin and DAPI; MCAs of
Vector-1, SKOV-3 and OVCA432 were stained with E-cadherin
as above. Images were taken using a Leica-TCS SP5 confocal
microscope (636and 206oil immersion objective lens for mono-
layer cells and MCAs respectively) and associated software. Z
section stacking images were generated using the Maximum
Projection software with aspect ratio 2.
Statistical Analysis
Student’s t-test was used for functional analyses with P#0.05
considered to be significant. For survival analysis, patients were
categorized into two groups with either low (n= 25) or high
(n= 13) KLK4 levels using a median cut-off of KLK4 copy number,
after normalization to 18S, of 0.0007 (range 0.0000147 to 0.0258).
Two different endpoints, cancer relapse and patient death were
used to calculate post-surgery progression free survival (PFS) and
overall survival time respectively. Kaplan-Meier analysis was used
to determine the association of KLK4 level with PFS and overall
survival time by a log rank model. The analyses were performed
using SPSS 18.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
KLK4-expressing SKOV-3 Cells are Less Migratory but are
Chemoresistant as 2D Monolayers
We wished to determine the mechanism of action underlying
the poor prognosis [24] and chemoresistance [25] previously
reported to be associated with high KLK4 levels in ovarian cancer
generally. Thus, we generated both stable and transient transfec-
tants in SKOV-3 cells that express little endogenous KLK4 for
functional analysis (Supplementary Fig. S1A). Western blot
analysis confirmed that the V5-tagged over-expressed KLK4
(33 kDa), an extracellular serine protease, is secreted in the
conditioned media (CM) of both stable and transient KLK4
transfectants but not vector-only, mock-transfected or native
SKOV-3 cells (Fig. 1A, top panel). Interestingly, an 88 kDa
protein band was seen in the CM from two of the high KLK4-
expressing clones (KLK4-1 and KLK4-2) and on transient
transfection, but not the CM of a serine to alanine active site
mutant-KLK4S207A (KLK4S/A) construct (Fig. 1A, top panel),
or the whole cell lysate (WCL) from wild-type KLK4 or mutant
KLK4S/A transfectants (Fig. 1A, bottom panel). These data
indicate that both wild-type KLK4 and mutant KLK4S/A are
secreted but only the wild-type KLK4 is present as an active
enzyme as shown by the 88 kDa band which is likely KLK4
covalently bound with an unidentified serpin. To support this
observation that KLK4 is activated and forms complexes with
serum borne proteins or inhibitors, active KLK4 (100 or 500 nM)
was incubated with culture medium (RPMI-1640), with or without
1% and 5% FCS for 2 and 18 h respectively. Western blot analysis
shows that the 88 kDa species is present only when active KLK4
was incubated in RPMI-1640 media with FCS but not when FCS
was absent (Supplementary Fig. S1B). The level of KLK4
expression in the KLK4-3 clone is comparable to that of
endogenous KLK4 expressing OVCA432 cells while the KLK4-
1 clone shows more intense KLK4 protein bands (Fig. 1B).
KLK4 and Chemoresistance in Ovarian Cancer
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Immunofluorescent (IF) microscopy using antibodies against the
V5-tagged C-terminus and N-terminal peptide of KLK4 [29]
further confirmed protein over-expression in each of the KLK4
clones, but negligible expression in vector control, native SKOV-3
cells or KLK4-1 IgG control (Fig. 1C, Supplementary Fig. S1C).
Previous in vitro studies have shown that KLK serine proteases
cleave collagens I and IV, fibronectin, vitronectin and laminin
[32,33] that are components of the peritoneal membrane [34] and
we reported that KLK7 over-expression increased adhesion to
fibronectin and vitronectin [23]. In this study, however, we did not
see any difference between the KLK4-transfected and control cells
in adherence to these ECM components or proliferation (data not
shown). On the other hand, KLK4 expressing clones showed less
transwell migration compared to vector/native control cells
(*P,0.05 or **P,0.01, Fig. 1D). In 2D-monolayer cultures, using
concentrations (cisplatin 0–50 mM; paclitaxel 0–100 mM) within
the range used for patient treatment (cisplatin 3–50 mM; paclitaxel
3–20 mM) [35], KLK4-transfected SKOV-3 cells were more
resistant to cisplatin than vector/native control cells (*P,0.05,
Supplementary Fig. S2, left panel), although only a trend towards
paclitaxel resistance was seen for KLK4-transfected cells (Supple-
mentary Fig. S2, right panel). These data suggest that any changes
induced by KLK4 over-expression were relatively subtle and that
cisplatin rather than paclitaxel resistance, as seen with KLK7
transfected SKOV-3 cells, would be the more clinically relevant
phenotype.
KLK4-expressing SKOV-3 Cells form Compact MCAs that
Spread on Mesothelial Cell Monolayers
Due to the role of homotypic cell adhesion for EOC cell survival
in the 3D-suspension microenvironment of ascites [36] and our
previous finding that KLK7 could induce spheroid formation [23],
we compared the ability of KLK4 transfected and control cells to
form MCAs/spheroids. By 1, 4 and 7 days post seeding, two of
three KLK4 clones generated large compact MCAs with more
cells while the lower KLK4-expressing KLK4-3 cells formed
slightly less compact MCAs, with vector controls and native
SKOV-3 cells forming small and scattered spheroids in 10% FCS
containing media (Fig. 2A). In support of this finding, the
endogenous KLK4 expressing OVCA432 cells formed more
compact MCAs than SKOV-3 cells that had little KLK4.
Quantitative analysis showed that KLK4-expressing cells formed
Figure 1. KLK4-expressing SKOV-3 cells are less migratory as 2D monolayers. A. Western blotting with anti-V5 antibody shows KLK4
expression in the conditioned media (CM) and whole cell lysate (WCL) from stable KLK4 tranfectants (KLK4-1, KLK4-2 and KLK-3; lanes 1–3), vector
(Vec-1, Vec-2 and Vec-3; lanes 4–6) and native SKOV-3 (lane 7) cells, and transiently expressed wildtype KLK4, mutant-KLK4S207A (KLK4S/A), vector
and mock transfectants (lanes 8–11); GAPDH was used as a loading control for WCL. B.Western blotting with anti-KLK4 antibody shows relative levels
of KLK4 protein in WCL of KLK4-1, KLK4-3 clones and OVCA432, and 10 ng of recombinant (r)KLK4 protein. C. IF microscopy with anti-V5/KLK4-N
terminal antibodies (green) and phalloidin (red) in KLK4-1, Vec-1 clones, native SKOV-3 or negative control (IgG). Scale bar, 20 mm. D. Transwell
migration assays with KLK4-1, KLK4-2, KLK4-3, Vec-1, Vec-2 and native SKOV-3 cells; n = 3, mean 6 SEM, *P,0.05.
doi:10.1371/journal.pone.0057056.g001
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more compact MCAs than vector control cells on day 1, 4
(**P,0.01) and 7 (***P,0.001, Fig. 2B), as did the endogenous
KLK4 expressing OVCA432 cells compared to SKOV-3 cells
(*P,0.05, Fig. 2B). As we have shown that some active KLK4 is
bound to unknown binding proteins or serpins in serum containing
media (Supplementary Fig. S1B) suggesting KLK4 enzymatic
activity could be inhibited in the presence of serum, we used serum
free conditions to test the addition of active KLK4. Under these
conditions, the KLK4-1 cells formed less compact MCAs (Fig. 2C)
than those seen in 10% FCS (Fig. 2A). Addition of recombinant
active KLK4 (rKLK4, 50 ng/ml) induced native SKOV-3 cells to
form MCAs more similar to that observed for the KLK4-1 clone
whereas the mutant KLK4S/A (catalytically inactive, 50 ng/ml)
treated SKOV-3 cells had a similar appearance to that of the
SKOV-3 cells treated with PBS as a control (P,0.05, Fig. 2C),
confirming the involvement of KLK4 activity in SKOV-3 cell
aggregation. Quantitative analysis showed that active rKLK4
treated SKOV-3 cells formed compact spheroids at a similar rate
to KLK4-1 cells, and both were greater than those treated with
non-active mutant KLK4S/A (*P,0.01) which was slightly
greater that that seen for the SKOV-3 control on day 4 and 7,
(**P,0.01, Fig. 2D). These data confirmed the role of the KLK4
peptidase in MCA formation but also suggested a possible non-
catalytic action of KLK4 in this process.
We then examined the invasiveness of KLK4-MCAs when
added onto peritoneal mesothelial cell monolayers. Bright-field
and fluorescent (CellTracker492) images show that the compact
KLK4-1 MCA adhered to the live LP9 mesothelial monolayer and
gradually formed an extensive front of spreading cancer cells over
3 days (Fig. 3A, top left panel) and up to 7 days (data not shown)
confirming their viability and growth on the mesothelial mono-
layer. The MCAs formed by vector-1 control cells also spread
across the mesothelial cell monolayer albeit to a less degree
(Fig. 3A, top right panel). The size of the foci generated by the
endogenously KLK4 expressing OVCA432 MCAs was similar to
those of the transfected KLK4-1 MCAs (Fig. 3A, bottom panel).
Quantitative analysis demonstrated that the diameter of the areas
of fluorescent KLK4 MCA clearance (.6 fold) was larger than
that of the Vector-1 clone (3.5 fold) on day 3 compared to their
clonal controls at 4 h (**P,0.01, Fig. 3B). Similarly, the diameter
of the KLK4 endogenously expressing OVCA432 MCA clearance
on day 3 (7 fold compared to 4 h) was comparable to that of the
KLK4-1 SKOV-3 clone while the native SKOV-3 MCA
clearance (3.2 fold compared to 4 h) was comparable to the
Vector transfected SKOV-3 cells (Fig. 3B). Confocal images show
that CellTracker492 stained KLK4-1, and endogenously KLK4
expressing OVCA432 MCAs stained with E-cadherin grew into
the mesothelial monolayers (Fig. 3C, top and middle panels) with
multiple Z stacking images confirming the clearance of mesothelial
monolayers by the MCAs to the bottom of the well (Fig. 3C, top
panels). Vector-1 and SKOV-3 MCAs can also invade into the
mesothelial monolayers but formed smaller invading foci due to
fewer cell numbers respectively (Fig. 3C, bottom panels). These
data suggest that the survival mechanism of cellular aggregation is
induced by KLK4 in the 3D-suspension ascites mimicking
microenvironment and that these KLK4 expressing spheroids will
have an increased spreading capacity into the mesothelial layer of
the peritoneum.
KLK4 Inhibition Increased Paclitaxel Sensitivity
Although KLK4-transfected SKOV-3 cells were more resistant
to cisplatin than vector/native control cells (Supplementary Fig.
S2, left panel), no difference in cisplatin responsiveness was seen
between KLK4 and vector/native control cells in 3D suspension
(data not shown). In contrast, although only a trend towards
paclitaxel resistance was seen for KLK4-transfected cells in 2D-
monolayer (Supplementary Fig. S2, right panel), KLK4-MCAs in
3D-suspension were clearly more resistant to paclitaxel than
vector/native cells (**P,0.01, Fig. 4A). Notably, compaction of
KLK4-1 MCAs was reduced by adding a KLK4 blocking
antibody at a concentration (10 mg/ml) to capture all active
enzyme or the selective active site KLK4 sunflower trypsin
inhibitor (SFTI-FCQR), compared to their appropriate controls
(Fig. 4B, left and middle panels). Similarly, compaction of the
endogenously expressing OVCA432 MCAs was reduced by
adding SFTI-FCQR (Fig. 4B, right panel). In addition, although
1 mM SFTI-FCQR alone did not reduce proliferation (data not
shown), it significantly reduced KLK4-1 and OVCA432 MCA
survival on combined treatment with paclitaxel (**P,0.01,
Fig. 4C). Interestingly, the general serine protease inhibitor,
aprotinin, partially reduced the compaction of MCAs formed by
KLK4-1 and OVCA432 cells (Fig. 4B, bottom panel) and
increased their sensitivity to paclitaxel (*P,0.05, Fig. 4C), albeit
to a lesser degree than SFTI-FCQR. These data emphasized that
KLK4-MCAs are resistant to paclitaxel and reduced MCA
compaction by KLK4 blockade increased sensitivity to this drug.
KLK4 Induced uPA Expression in SKOV-3 Cells
Given that aprotinin can also inhibit the action of other serine
proteases, such as uPA that was activated by KLK4 in previous
biochemical studies [17,18], we examined the expression of uPA in
KLK4 transfected SKOV-3 cells. We observed that whole cell
lysates of KLK4 transfected SKOV-3 clones, KLK4-1, KLK4-2
and KLK4-3, displayed intense uPA bands at ,48 and 38 kDa
compared to vector and native SKOV-3 control cells on Western
blot analysis (Fig. 5A). However, there is essentially no difference
in protein band intensity of a5 (Fig. 5A) or b1 integrin (data not
shown) observed in KLK4 clones compared to control cells. These
data from KLK4 expressing cells are different from the
upregulated expression of a5/b1 integrins observed in KLK7
transfected SKOV-3 cells [23], and underscore the different
pathways modulated by each KLK family member. To examine if
the increased uPA is induced by KLK4 over-expression, KLK4
knockdown was performed in the KLK4-1 transfected SKOV-3
cells. Western blotting on whole cell lysates from these cells showed
that expression of uPA was also reduced (Fig. 5B), confirming that
KLK4 over-expression induces uPA in SKOV-3 cells. Interest-
ingly, expression of both KLK4 and uPA was only observed when
KLK4-1 cells were cultured as a 2D-monolayer or in 3D-
suspension, but not on 3D matrices of type I collagen or Matrigel
(Fig. 5C), further suggesting a specific association of these two
proteases with different 3D microenvironments. Importantly,
Western blotting and densitometry analysis showed co-expression
and significantly high protein levels of both KLK4 and uPA in
ascitic EOC cells (4/6, Fig. 5D–E) compared to cells derived from
the primary tumor of these patients. The slightly different
molecular weight of these proteases in individual patient samples
may reflect their post-translational modification, such as glycosyl-
ation of KLK4 as we and others have reported previously [29,37].
These data suggest that the 3D-suspension microenvironment
reprograms the expression of these proteases in EOC cells which is
reflected in the differential expression of KLK4 and uPA as seen in
ascitic compared to primary EOC cells.
KLK4 is Associated with Poor Outcome of Patients with
Serous EOCs
To further determine the clinical relevance of KLK4 induced
MCAs observed in vitro, the morphology of ascitic MCAs from
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Figure 2. KLK4-expressing SKOV-3 cells form compact MCAs in a 3D-suspension microenvironment. A. MCA/spheroid formation
conducted in 10% FCS containing media at 4 h, day 1, 4 and 7, with representative images of KLK4-1, KLK4-2, KLK4-3, Vec-1, Vec-2 clones, native
SKOV-3 and endogenous KLK4 expressing OVCA432 cells. B. Quantitative analysis of percentage of 4 h (0 time point) that formed compact MCAs
($30 mm) after 1, 4 and 7d from the 3 KLK4 clones combined, 2 vector clones combined, native SKOV-3 and OVCA432 cells. C. MCA formation under
serum free conditions by KLK4-1 clone and native SKOV-3 cells treated with 50 ng/ml active recombinant (r)KLK4or mutant-KLK4S207A (KLK4S/A) and
PBS control at day 1, 4 and 7. D. Quantitative analysis of compact MCA formation of KLK4-1, SKOV-3 treated with rKLK4, KLK4S/A and PBS as a control
over 1, 4 and 7d. For panels A and C, scale bars, 200 mm; for B and D, the experiment was repeated 3 times with triplicates; mean 6 SEM; *P,0.05;
**P,0.01; and ***P,0.001.
doi:10.1371/journal.pone.0057056.g002
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EOC patients was compared with KLK4 transfected cells. Trypan
blue stained KLK4-1 MCAs displayed a similar appearance to the
EOC spheroids derived from ascites (Fig. 6A). IF microscopy
images showed that KLK4 was localized in the cytoplasm of
ascites-derived MCAs from 2 patients (Fig. 6B).
To determine the association of high KLK4 levels with prognosis
in EOC specifically, compared to that reported previously for
ovarian cancer patients with mixed histotypes [24,25], we
performed RT-qPCR in a cohort of cDNA samples from 38
serous EOC patients. Kaplan-Maier survival analysis showed that
the patients with high tumor KLK4 had significantly shorter
progression free (PFS, x2 = 8.3, P= 0.004) and overall survival
time (x2 = 4.9, P = 0.03) than those with low KLK4 (Fig. 6C).
Pearson Correlation analysis revealed an association of high KLK4
levels with late stage (P= 0.017), large residual tumor volume
(P = 0.034) and no-response to chemotherapy (P= 0.03) but not
the tumor grade (P= 0.95), tumor origin (primary or metastatic
sites, P = 0.59) or ascites volume (P= 0.38, Supplementary Table
S2).
Discussion
We report here that KLK4 over-expression promotes MCA/
spheroid formation and paclitaxel resistance in a 3D-suspension
microenvironment akin to that seen in ascites, and increases
spreading of these cells on a mesothelial monolayer, important in
EOC invasive behavior. KLK4 inhibition reduced MCA com-
paction and increased sensitivity to paclitaxel confirming the
integral role of KLK4 in these events. Although these data were
generated in only two serous ovarian cancer cell lines (SKOV-3
and OVCA432) and may not be representative of all serous EOC,
they support our own findings here in a serous EOC cohort, and
previous reports in ovarian cancer cohorts of mixed histotypes
[24,25], that women with high KLK4 mRNA levels in their tumors
had shorter progression free and overall survival time. Notably, the
Figure 3. MCAs clear mesothelial monolayers mimicking invasion into the peritoneal membrane. A. Bright-field and fluorescence
(CellTracker492) images show KLK4-1, Vector-1, SKOV-3 and OVCA432 MCA (4 h and day 3) clearance of mesothelial monolayers. Discontinuous lines
indicate perimeters of the spreading MCAs. B. Quantitative analysis shows the average diameter of 10 MCAs from 3 separate experiments for above
cell lines at 4 h and day 3 respectively; mean 6 SE, n = 3, **P,0.01. C. IF microscopy images show mesothelial monolayer clearance of MCAs formed
by KLK4-1 labeled with CellTracker492, Vector-1, OVCA432 and SKOV-3 cells stained with an E-cadherin antibody (green); both MCAs and mesothelial
LP9 cells were stained with Phalloidin for F-actin (Alexa Flour 568, red) and DAPI for nuclei (blue) respectively; discontinuous lines indicate positions of
multiple Z sections shown as right and bottom panels. For panels A and C, scale bars, 50 mm.
doi:10.1371/journal.pone.0057056.g003
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latter cohorts consisted of largely serous EOC patients (64/145, ref
[24]; 38/46, ref [25]). Overall, these findings indicate that KLK4
not only has potential as a prognostic biomarker, but as a
therapeutic target to increase paclitaxel sensitivity for a subgroup
of EOC patients with high KLK4 levels.
The host microenvironment reprograms cell phenotypes pro-
moting cancer progression including peritoneal metastasis of EOC
[13]. Multicellular aggregation is one such event that aids tumor
cells to survive in a 3D-suspension ascites microenvironment via
reprogramming cellular phenotype and relevant molecules, such
as integrins [36,38]. Our previous study showed that the KLK7
peptidase promotes MCA formation and cell-ECM interaction via
a5b1 integrins [23]. However, in contrast to the KLK7-expressing
SKOV-3 clones, KLK4-expression in SKOV-3 cells did not
increase a5b1 integrin levels compared to the vector/native cells
but induced expression of uPA, suggesting different molecular
mechanisms are involved. Furthermore, in contrast to the
preferable adhesion to fibronectin and vitronectin, but not type I
or IV collagen, observed in KLK7-SKOV-3 cells [23] KLK4-
SKOV-3 cells did not show increased adhesion to any of these
ECM proteins. However, more compact MCAs still formed in the
ascites mimicry 3D-suspension microenvironment when KLK4
was over-expressed in, or when active KLK4 was added to,
SKOV-3 cells. Like the KLK7 spheroids [23] the KLK4-MCAs
were able to invade into mesothelial cell monolayers and produced
larger cancer cell foci than those formed by vector and native
SKOV-3 cells. Although the less compact Vector-transfected and
native SKOV-3 MCAs can also re-grow into mesothelial
monolayers, the larger compact KLK4 SKOV-3 MCAs with
more cells likely generate more contractile force to drive
mesothelial cells apart, mimicking the invasive EOC phenotype
as reported previously [31,39,40].
Chemoresistance is a major obstacle to conquer in prolonging
the survival time of ovarian cancer patients. In addition to the
chemoresistance observed with MCAs compared to monolayer
cells [41], compact MCAs are less responsive to various treatments
including chemotherapies than scattered small ones [42]. The
penetrating gradient of cytotoxic drugs has an impact on their
uptake by the cells in the centre of MCAs as it does on nutrients
and oxygen [42]. That platinum resistance is related to cellular P-
glycoprotein level but not the hypoxic status [43] may explain why
we saw no difference in cell survival between the compacted
KLK4-expressing and scattered control SKOV-3 MCAs on
platinum treatment. However, the paclitaxel resistance seen in
compact KLK4-MCAs may be associated with hypoxia in the
inner cell mass of MCAs [44]. Blocking certain peptidases using a
small molecule inhibitor may be a potential adjunct therapeutic
strategy as we saw that the addition of a KLK4 inhibitory antibody
or selective KLK4 active site inhibitor (SFTI-FCQR) [27]
increased paclitaxel sensitivity of MCAs formed by KLK4
expressing cells. Consistent with this observation, adding the
general serine protease inhibitor, aprotinin, also showed reduced
compaction of KLK4-MCAs and increased response to paclitaxel
although to a lesser degree. This suggests a complex interplay of
serine proteases such that blocking their activity with aprotinin
may in some cases enhance their resistance to paclitaxel. However,
our data is consistent with a previous observation in a xenograft
mouse model showing that a combined regime of the general
Kunitz-type serine protease inhibitor bikunin and paclitaxel
Figure 4. Inhibition of KLK4 increased paclitaxel sensitivity.
WST-1 assay shows cell survival of KLK4-1, KLK4-2, KLK4-3, Vec-1, Vec-2
clones and native SKOV-3 MCAs after paclitaxel (A) treatment in 3D-
suspension. B. Left panel, representative images of KLK4-1 MCAs on day
4 with mouse IgG and a functional KLK4 blocking antibody, PBS as a
control and KLK4 selective inhibitor SFTI-FCQR (SFTI) as indicated. Right
panel, representative images of OVCA432 MCAs on day 4 with PBS as a
control and KLK4 selective inhibitor SFTI-FCQR (SFTI) or aprotinin as
indicated. Scale bars, 200 mm. C. Cell survival determined by WST-1
assay after treatment with paclitaxel (Pac) on 3D-suspension cultured
KLK4-1 clone and OVCA432 cells +/21 mM SFTI or 5 mM aprotinin
(Aprot). Experiments in panels A and C were repeated 3 times in
triplicate, bars represent Mean 6 SEM. Statistical significance indicated
as *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0057056.g004
KLK4 and Chemoresistance in Ovarian Cancer
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e57056
reduced intra-peritoneal tumor burden and ascites volume [45].
Interestingly, a previous study showed an association of uPA
expression and chemoresistance in ovarian cancer patients [10]. In
addition, the clearance of mesothelial monolayers may also reflect
a role of uPA secreted by EOC cells in the MCAs or other
potential mechanisms yet to be determined. Whether this is a
downstream event of KLK4 activation remains to be determined.
These data suggest that KLK4 and other KLK serine peptidases,
such as KLK7 [23], play a role, at least in part, in MCA related
chemoresistance.
KLK4 is synthesized as a pre-pro-enzyme with signal peptide
cleavage during secretion; after secretion the pro-region is
cleaved to activate KLK4. To date there is no published
literature regarding the auto-activation of KLK4 or activation of
this enzyme in cancer cells. However, it has been reported that
KLK4 can be activated by MMP20 during tooth development
in the pig [46,47] suggesting that MMP20 or an MMP with a
similar specificity may activate KLK4 in the ovarian cancer
microenvironment. The active KLK4 enzyme can bind to
serpins to form a covalent complex, such as a1-antitrypsin and
a2-antiplasmin [48]. We have provided evidence that the
88 kDa band observed here may reflect a bound form of
KLK4 to a serum binding protein or serpin since the KLK
peptidases are known to covalently bind through their active site
to serpins [49]. Similarly, our data suggests that the KLK4
secreted by the KLK4-transfected SKOV-3 cells was active
since it formed a high molecular weight complex in the
presence of serum while the catalytically inactive mutant-
KLK4S/A did not form such a complex. Thus, a complex
regulatory system, similar to uPA regulation by PAI-1 [50,51],
likely exists for the KLK peptidases in the ovarian cancer ascites
microenvironment. Indeed, several KLKs, such as KLK6 and
KLK7, have been identified in ascites derived from women with
EOC using unbiased proteomic approaches [52,53]. In addition,
KLKs regulate cell signaling pathways via extracellular proteol-
ysis [14]. For example, at a biochemical level, active KLK4
cleaves pro-uPA generating active single chain uPA [17] which
is induced by ascites in EOC cells [9] and is associated with
chemoresistance and poor prognosis in women with this cancer
[10,11]. Furthermore, high levels of KLK5-KLK8 and uPA
have been associated with late stage ovarian cancer in patients
who have already developed metastasis [54]. Both preclinical
in vitro and in vivo studies revealed that inhibition of tumor
associated uPA reduced invasive behaviors of cancer cells [50],
but the effects of its inhibitors were minimal in clinical trials
[51]. In this study, we showed for the first time that KLK4
induced expression of pro-uPA in SKOV-3 EOC cells providing
a possible molecular mechanism by which KLK4 promotes
invasive behaviors and chemoresistance via its downstream
targets. Although the precise substrate(s) cleaved by KLK4 that
are important in the MCA formation and chemoresistance
observed here remain to be clarified, pro-uPA is a promising
candidate. Our data showing KLK4 expression in ascites-
derived EOCs is consistent with a previous clinical observation
Figure 5. KLK4 induced uPA expression in SKOV-3 cells. A.Western blot analysis shows expression of uPA, a5 integrin (ITN) and KLK4 (V5) of 3
KLK4 and 3 vector control clones with native SKOV-3 cells as a control with GAPDH as a loading control. B.Western blot analysis shows expression of
KLK4 and uPA in KLK4-1 clone transfected with siRNA KLK4 exon 1 (psilK4Ex1), and both KLK4 exon 1 and 2 knockdown constructs (psilK4Ex1+2), p-
silencing scramble (psil Ctl) and mock controls. GAPDH was used as a loading control. C.Western blotting shows expression of KLK4 and uPA in KLK4-
1 cells cultured as 2D-monolayers (2D), 3D-collagen I (Col I), 3D-Matrigel (Matrigel), and 3D-suspension (Susp), with GAPDH as a loading control. D.
Western blot shows expression of KLK4 and uPA in serous EOC cells of primary tumors (T) and ascites (A) from 6 patients. WCL of OVCA432 MCAs
serves as a positive control and GAPDH as a loading control. E. Densitometry analysis of 3 Western blots indicative of that shown in D. **P,0.05 and
***P,0.001 indicate the significantly different levels of KLK4 and uPA in ascitic (A) and primary tumor cells (T).
doi:10.1371/journal.pone.0057056.g005
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of high KLK4 levels in EOC samples from patient effusions
[55] which further supports our overall findings here, and that
of others, that high KLK4 levels are associated with EOC
progression and chemoresistance [24,25]. These findings may
also reflect high KLK4 levels in ascites fluid although previous
studies showed a low level of KLK4 in ascites or effusions from
ovarian cancer patients [56,57], In the future, it will be
important to correlate KLK levels in ascites with that in cells
derived from ascites as well as serum to determine the
prognostic utility of such information. The concurrent expres-
sion of uPA in these cells strongly suggests an association that
may involve a hierarchical cascade of serine protease activation.
However, the increased blockade of KLK4 action by the
selective KLK4 inhibitor, SFTI-FCQR, compared to that seen
with aprotinin suggests that other, as yet unidentified, substrates
of KLK4 must also be involved.
Our data that adding active rKLK4 significantly increased
compaction of MCAs formed by SKOV-3 cells compared to the
inactive mutant KLK4S/A and PBS controls support a role for
KLK4 enzymatic activity in this process. However, it is notable
that when inactive mutant KLK4S/A was added into the SKOV-
3 cultures, the MCAs formed were more compact than controls,
suggesting that not only the KLK4 enzyme but the inactive
KLK4S/A also plays a role in MCA formation. These data
indicate that the action of KLK4 in MCA formation involves both
proteolytic and nonproteolytic effects. Thus, conceivably the
KLK4 functional blocking antibody is also inhibiting non
proteolytic KLK4 effects although the data from the use of the
KLK4 selective active site SFTI inhibitor clearly indicates that
there is a significant proteolytic component to this effect as well.
Consistent with this argument, a recent study showed that
catalytically inactive KLK10, another member of this gene family,
Figure 6. KLK4 is associated with poor outcome of patients. A. Phase contrast images show the similar morphology of trypan blue stained
KLK4-1 MCAs and ascites-derived MCAs from a serous EOC patient. Scale bar, 50 mm. B. IF confocal microscopy with an antibody against KLK4
(green), phalloidin (red) and DAPI (blue) in ascitic serous EOC MCAs from 2 patients; scale bars, 25 mm. C. Kaplan-Meier survival analysis shows the
relationship between KLK4mRNA levels in tumor tissue samples and survival status of a cohort of 38 serous EOC patients. Left panel, progression free
survival (PFS) time for patients with low KLK4 (n = 25) and high KLK4 (n = 13) levels (x2 = 8.3, p=0.004). Right panel, overall survival time for patients
with low KLK4 (n = 25) and high KLK4 (n = 13) levels (x2 = 4.9, p=0.03).
doi:10.1371/journal.pone.0057056.g006
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displayed a role as a tumor suppressor on ES2 ovarian cancer cells
both in vitro and in vivo [58]. An earlier study revealed that two
prostate specific antigen (PSA, also known as KLK3) blocking
antibodies, one inhibiting enzymatic activity and one not affecting
catalytic activity, both inhibited the biological function of this
kallikrein, suggesting that PSA also has an alternative function via
protein-protein interaction [59]. Together, these data may also
reflect the evolutionary similarity that these kallikreins share with
growth factors like nerve growth factors [60] which may in part
explain any spatially induced protein-protein interactions.
In summary, we have provided a mechanism for the functional
role of KLK4 in EOC progression by promoting MCA formation
and chemoresistance in the 3D-suspension microenvironment seen
clinically in ascites. Thus KLK4 inhibition may be a potential
enhancer of paclitaxel sensitivity for a subgroup of serous EOC
patients with high KLK4 levels.
Supporting Information
Figure S1 A. RT-PCR showing expression of KLK4 (K4Ex1-
For, 59-ATGGCCACAGCAGGAAATCCC-39; K4Ex4Rev, 59-
CACGCACTGCAGCACGGTAG-39) in EOC cell lines OV90,
Caov-3, OVCA420, PEO1, PEO4, PEO14, OVCA432, OAW42
and OVCAR-3, but not mesothelial LP9, normal ovarian
epithelial HOSE17.1, EOC SKOV-3, OVMZ-6 or NFF cells
with no cDNA as negative control. b2-microglobulin (b2M)
(b2MFor, 59- TGAATTGCTATGTGTCTGGGT-39, b2MRev,
59- CCTCCATGATGCTGCTTACAT-39) serves as a loading
control. B. Recombinant active KLK4 bound to unknown
serpins/proteins in the FCS containing media. Western blot
analysis using anti-V5 primary antibody as described in Materials
and Methods showing the 88 kDa protein band formed by
recombinant active KLK4 at concentration of 100 nM or 500 nM
in the presence of either 1% or 5% FCS containing RPMI-1640 at
time points 2 h (Lanes 1–7) and 18 h (Lanes 8–14) respectively.
Precision Plus Protein Dual Color Standards #161-0374EDU
were from Bio-Rad with molecular weight (kDa) indicated. Lanes
1 and 8, KLK4 500 nM in PBS; 2 and 9, KLK4 100 nM in
RPMI-1640; 3 and 10, KLK4 500 nM in RPMI-1640; 4 and 11,
KLK4 100 nM in RPMI-1640 with 1% FCS; 5 and 12, KLK4
500 nM in RPMI-1640 with 1% FCS; 6 and 13, KLK4 100 nM
in RPMI-1640 with 5% FCS; 7 and 14, KLK4 500 nM in RPMI-
1640 with 5% FCS respectively. C. Immunofluorescent micros-
copy confirmed KLK4 protein expression in SKOV-3 cells stably
over-expressing KLK4 clones but not in Vector-1, native SKOV-3
control cells or IgG negative control on KLK4-1. KLK4 is in
green detected by antibody against V5 or KLK4 and phalloidin
staining F-actin in red. Scale bar, 20 mm.
(TIF)
Figure S2 KLK4 overexpressing SKOV-3 cells are che-
moresistant. Left panel, WST-1 assay shows cell survival after
cisplatin treatment in KLK4-SKOV-3 cells compared to vector
control cells in 2D-monolayer conditions (72 h treatment),
*P,0.05. Right panel, KLK4-SKOV-3 cells appear resistant to
paclitaxel in 2D-monolayer culture but this does not reach
significance. Mean 6 SEM of 3 KLK4/vector-SKOV-3 clones
from 3 separate experiments in triplicates.
(TIF)
Table S1 Clinical, pathological characteristics and
KLK4 levels of patients. 1Patients were classified into 3 groups
based on chemotherapy response and clinical observations. 2WD,
MD, PD=well, moderately or poorly differentiated, U=un-
known. 3G= gross amount of tissue remaining. 41u=cancerous
ovarian tissue, 2u=diseased adjacent metastatic tissue. Ascites:
L=Large, .5,000 ml; M=med, 1,000–5,000 ml; S = small,
,1,000 ml; or 0 =nil; U=unknown. 5Chemo-treatment: C= car-
boplatin, T=Taxol, CT= carboplatin and taxol, CTG= carbo-
platin, taxol and gemcitabine, clinical trial, U= unknown;
Chemotherapy notes: 6patient had 3 cycles of chemotherapy
pre-surgery to reduce tumor load, then had normal chemotherapy
after surgery. 7Patient had 2 cycles and died. 8N=no chemother-
apy, patient died with brain metastases. 9Patient had previous
surgery, no previous chemotherapy. 10Recurerent cancer, original
chemotherapy was CT. 11CT for 1 cycle then carboplatin only for
5 cycles. 12Progression free survival. 13KLK4 levels in tumor
samples, H=high, L= low. 14Y= deceased, N= alive.
(DOC)
Table S2 Relationship between KLK4 levels and clinical
parameters in 38 serous EOC patients. *One way Pearson
analysis was performed for association of KLK4 levels and stage,
grade, residual tumor size, origin, ascites volume and chemo-
response respectively. p,0.05 is statistically significant.
(DOC)
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